Semaglutide (Wegovy®)

Clinical Indication

Weight management in overweight and obese adults


Work is ongoing locally to plan for the implementation of NICE TA875. Semaglutide will only be available to patients that meet the eligibility criteria outlined by NICE and only through a specialist weight management service.

Date of classification

June 2023

Do not prescribe

Drugs not recommended for use in LLR because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.